[1]
Augustin, M., Wegtowska, J., Lebwohl, M., Paul, C., Piguet, V., Sofen, H., Blauvelt, A., Peterson, L. and al., E. 2018. Durability of Response in Patients with Chronic Plaque Psoriasis Treated with Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT). SKIN The Journal of Cutaneous Medicine. 2, (Dec. 2018), S87. DOI:https://doi.org/10.25251/skin.2.supp.88.